Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study proposes to prove that the efficacy of adjuvant endocrine therapy for the
premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy
assessed by ultrasound response rate.